^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    1d
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    1d
    FAM135B suppresses glioblastoma angiogenesis via stabilizing the IKK complex and inactivating the NF-κB/IL-6 signaling pathway. (PubMed, J Transl Med)
    FAM135B acts as a critical negative regulator of GBM angiogenesis, whose low expression contributes to high tumor angiogenic potential and poor patient prognosis. Mechanistically, HNF4A transcriptionally upregulates FAM135B, which then binds to and stabilizes the IKK complex, inactivating the NF-κB signaling pathway and downregulating IL-6 expression, ultimately inhibiting the JAK/STAT-mediated angiogenic process. FAM135B also remodels the GBM tumor microenvironment by reducing M2 macrophage infiltration. Targeting the HNF4A/FAM135B/NF-κB/IL-6 signaling axis provides a novel and promising therapeutic strategy for GBM anti-angiogenic therapy.
    Journal
    |
    IL6 (Interleukin 6) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • HNF1A (HNF1 Homeobox A)
    |
    Avastin (bevacizumab)
    1d
    POYANG: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov)
    P3, N=280, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    2d
    Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=33, Completed, Sam Chun Dang Pharm. Co. Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    2d
    Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Aveta Biomics, Inc. | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab)
    2d
    A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM (clinicaltrials.gov)
    P2, N=31, Completed, Biotheus Inc. | Recruiting --> Completed | N=55 --> 31 | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • pemetrexed • pumitamig (BNT327)
    2d
    Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review. (PubMed, Gynecol Oncol Rep)
    Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib...Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Zejula (niraparib)
    3d
    Gineco-ov133b: REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. (2025-524232-20-00)
    P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018) • Neupogen (filgrastim)
    5d
    A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC (clinicaltrials.gov)
    P3, N=280, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | Trial completion date: Dec 2018 --> Dec 2026 | Trial primary completion date: Dec 2017 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
    5d
    Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P2, N=15, Recruiting, Adverum Biotechnologies, Inc.
    New P2 trial
    5d
    Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, University of Oklahoma | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    6d
    Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, University of Cincinnati | Trial completion date: Jun 2029 --> Dec 2029 | Initiation date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jun 2028 --> Dec 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Avastin (bevacizumab)